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Abstract (word limit = ~250; actual = 301)  
Background: MOBILE and ENHANCE were similarly-designed randomized trials of walking-
impaired adults with either relapsing-remitting or progressive multiple sclerosis (MS) who were 
treated with either placebo or 10 mg prolonged-release (PR)-fampridine twice daily for 24 
weeks. Both studies showed that PR-fampridine treatment led to sustained and clinically 
meaningful improvement in broad measures of walking and balance over 24 weeks.  
Objective: To evaluate the efficacy of PR-fampridine vs placebo using a post hoc integrated 
efficacy analysis of MOBILE and ENHANCE data. 
Methods: Data from the intention-to-treat (ITT) populations of MOBILE and ENHANCE studies 
were pooled in a post hoc efficacy analysis based on the following outcome measures: Timed 
Up and Go [TUG] speed, Berg Balance Scale [BBS], 12-item MS Walking Scale [MSWS-12]), 
MS Impact Scale physical impact subscale [MSIS-29 PHYS], and EuroQol 5-dimensions (ED-
5D) visual analogue scale (VAS) and utility index score. The primary analysis was the 
proportion of PwMS with a mean improvement in MSWS-12 score (≥8 points) from baseline 
over 24 weeks; prespecified subgroups were stratified by demographics and disease 
characteristics. 
Findings: In the ITT population (N = 765; PR-fampridine [n = 383]; placebo [n = 382]), a greater 
proportion of PR-fampridine–treated PwMS than placebo-treated PwMS achieved a clinically 
meaningful improvement in the MSWS-12 scale over 24 weeks (44.3% vs 33.0%). PR-
fampridine MSWS-12 responders demonstrated greater improvements from baseline in TUG 
speed, BBS score, MSIS-29 PHYS score, and EQ-5D VAS and utility index scores versus PR-
fampridine MSWS-12 nonresponders and placebo. Subgroup analyses based on demographic 
and disease characteristics at baseline showed consistency in the effects of PR-fampridine 
across different subgroups. 
Conclusions: The pooled analysis of MOBILE and ENHANCE strengthens previous evidence 
that treatment with PR-fampridine results in clinically meaningful improvements in walking, 
physical function, mobility and balance, and quality of life and is effective across a broad range 
of PwMS. 
Keywords: Fampridine, balance, walking, multiple sclerosis. 
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Introduction  
Impaired mobility is the hallmark physical manifestation of multiple sclerosis (MS), reported by 
45%, 67% and 93% of people with MS (PwMS) within 1 month, 2 years, and 10 years of 
diagnosis, respectively [Van Asch, 2011]. Commonly reported deficits in mobility include walking 
difficulty, and gait and coordination abnormality [Martin et al., 2006, Van Asch, 2011]. The 
emergence of mobility deficits early in the disease course suggests that motor performance 
deteriorates before clinical signs of pyramidal dysfunction [Martin et al., 2006, Van Asch, 2011]. 
As MS tends to present between the ages of 20 and 40 years when individuals are in their prime 
[Freedman, 2006], the inevitable lack of mobility is a highly emotive concern for PwMS who 
describe some of their feelings as ′limited′, ′powerless′, ′frustrated′, and ′frightened′ [Van Asch, 
2011]. The family, social and working lives of PwMS can be compromised severely by mobility 
and walking impairments [Van Asch, 2011].  
Management of MS requires lifelong disease-modifying therapy (DMT) to reduce 
disease activity along with treatment of individual symptoms to improve quality of life [Thompson 
et al., 2010, Giovannoni et al., 2016]. Although there is some evidence that new DMTs can 
delay disability progression [Wiendl et al., 2015], there have been no randomized, controlled 
clinical trial data showing that DMTs can improve ambulatory function in MS. Findings from 
meta-analyses indicate that exercise training can improve walking capacity only modestly 
among PwMS [Snook et al., 2009, Paltamaa et al., 2012, Pearson et al., 2015].  
Prolonged-release (PR) fampridine (known as dalfampridine extended-release tablets in 
the United States) is a twice-daily oral symptomatic therapy indicated for the improvement of 
walking in PwMS with walking disability (defined as Expanded Disability Status Scale [EDSS] 
score between 4.0 and 7.0). PR-fampridine is thought to block voltage-dependent potassium 
channels, resulting in improvements in action potential conduction in demyelinated nerve fibers 
[Judge et al., 2006].  
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In two multicenter, randomized, double-blind, phase 3 trials, PR-fampridine 
demonstrated improvements in walking speed versus placebo, as measured by the objective 
timed 25-foot walk (T25FW) [Goodman et al., 2009, Goodman et al., 2010]. Additionally, a 
strong efficacy signal was evident in an open-label extension study of the two phase 3 clinical 
trials [Goodman et al., 2015], whereby improvements in walking speed were lost after PR-
fampridine was discontinued in the parent trial only to return by the 2-week assessment after re-
initiation of the drug. In the phase 3 pivotal trials, participants treated with PR-fampridine who 
were considered responders on the T25FW test rated their improvement in walking speed as 
clinically meaningful on the self-reported 12-item Multiple Sclerosis Walking Scale (MSWS-12) 
[Hobart et al., 2003, Goodman et al., 2009, Goodman et al., 2010]. These results demonstrated 
that treated participants were aware of their improvement in walking disability, but were 
regarded as tentative confirmation of the objective findings because of complexities and 
limitations inherent in individuals’ self-assessments of health. 
MOBILE was a 6-month exploratory phase 2 study that evaluated the effects of 
prolonged-release fampridine (PR-FAM) versus placebo on self-reported walking and balance in 
PwMS with walking disability [Hupperts et al., 2016]. Based on data from MOBILE, a reduction 
of ≥8 points in mean score was identified as the threshold for a clinically meaningful 
improvement in MSWS-12 score in individuals with MS [Mehta et al., 2015].  
The phase 3 ENHANCE study was a randomized, double-blind, placebo-controlled study 
similar in design to MOBILE [Hobart et al., 2019]. The ≥8-point threshold for a clinically 
meaningful improvement in MSWS-12 score was the a priori primary endpoint in ENHANCE 
[Hobart et al., 2019], which was identified using data from the MOBILE study [Mehta et al., 
2015]. Walking-impaired PwMS treated with PR-fampridine 10 mg twice daily had a greater 
likelihood of experiencing clinically meaningful improvements in self-reported walking ability 
over 24 weeks compared with placebo (odds ratio, 1.61; 95% confidence interval 1.15−2.26; 
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p=0.006) [Hobart et al., 2019]. PR-fampridine also demonstrated benefits versus placebo on MS 
Impact Scale physical subscale (MSIS-29 PHYS) score. 
Here, we report the results of a post hoc integrated analysis of individual-level data from 
the MOBILE and ENHANCE studies to further characterize the impact of PR-fampridine on 
several efficacy outcomes. 
 
Methods 
Study design and participants 
Independent ethics committees or institutional review boards approved the MOBILE 
(NCT01597297) and ENHANCE (NCT02219932) study protocols and all their amendments. 
Details of the MOBILE and ENHANCE study designs have been previously described [Hupperts 
et al., 2016, Hobart et al., 2019]. Combining individual-level data from MOBILE and ENHANCE 
was appropriate because of the many similarities and only slight differences between their 
methodologies (Figure 1) [Hupperts et al., 2016, Hobart et al., 2019]. Both studies featured 
multicenter, randomized, double-blind, parallel-group designs that evaluated the effects of 24 
weeks’ PR-fampridine 10 mg twice daily versus placebo in PwMS using the same efficacy 
endpoints [Hupperts et al., 2016, Hobart et al., 2019]. 
The inclusion/exclusion criteria of the studies were highly comparable, namely, 
enrollment of participants aged 18–70 years with a diagnosis of primary-progressive MS 
(PPMS), secondary-progressive MS (SPMS), progressive-relapsing MS (PRMS), or relapsing-
remitting MS (RRMS) per revised McDonald criteria[Mcdonald et al., 2001, Polman et al., 2005] 
of at least 3 months duration [Hupperts et al., 2016, Hobart et al., 2019]. Also mandatory for 
inclusion was an Expanded Disability Status Scale (EDSS) score of 4−7 [Hupperts et al., 2016, 
Hobart et al., 2019]. Presence of a walking impairment (as deemed by the investigator) was an 
inclusion criterion of ENHANCE only. 
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Assessments 
Psychometrically validated outcome measures evaluated in this pooled analysis were those 
used in both of the individual trials. Self-reported walking ability was assessed using the MSWS-
12 (used for the primary endpoint in ENHANCE) [Hobart et al., 2019]. Objectively-assessed 
mobility and dynamic balance were assessed using the Timed Up and Go (TUG) test [Podsiadlo 
et al., 1991, Cattaneo et al., 2006], and clinician-reported static and dynamic balance were 
measured using the Berg Balance Scale (BBS) [Cattaneo et al., 2006, Cattaneo et al., 2007]. 
The impact of MS on the individual and quality of life were assessed using the MSIS-29 PHYS 
[Hobart et al., 2001], as well as the generic EuroQol 5-dimensions (EQ-5D), visual analogue 
scale (VAS) and utility index score [Euroqol Group]. The 5-level classification system of the EQ-
5D (EQ-5D-5L) was used in MOBILE [Hupperts et al., 2016] whereas the 3-level EQ-5D (EQ-
5D-3L) was used in ENHANCE [Hobart et al., 2017]. To pool these data sets, the “crosswalk” 
method, developed by the EuroQol Group, was used to map the EQ-5D-5L data to the EQ-5D-
3L UK value set before calculating the utility index score [Van Hout et al., 2012]. 
Study visits were scheduled at screening, day 1, weeks 2, 4, 8, 12, 16, 20 and 24 of the 
on-treatment period, and at the week 26 follow-up visit in MOBILE and ENHANCE (Figure 1) 
[Hupperts et al., 2016, Hobart et al., 2019]. The MSWS-12, TUG, and MSIS-29 PHYS (except 
week 26) questionnaires were completed at these times in both studies. The BBS was also 
assessed at these times in MOBILE but less frequently on treatment in ENHANCE. The EQ-5D 
was administered at all on-treatment visits with the exception of week 2 in MOBILE and 
administered at day 1, and weeks 2, 4 and 24 in ENHANCE. 
 
Statistical analyses 
These post hoc pooled analyses were performed on the intention-to-treat (ITT) populations of 
the MOBILE and ENHANCE studies, defined as all randomized participants who received at 
least one dose of study drug and had at least one efficacy assessment post-baseline [Hupperts 
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et al., 2016, Hobart et al., 2019]. For analysis of MSWS-12, BBS, and MSIS-29, baseline was 
defined as the mean of the screening and Day 1 visits. For analysis of EQ-5D utility index and 
VAS, baseline was defined as day 1 only, given that this parameter was not measured at 
screening.  
The primary analysis was the proportion of PwMS with a mean improvement in MSWS-
12 score exceeding the predetermined threshold (≥8-points) from baseline over 24 weeks (i.e., 
PR-fampridine responders), analyzed using a logistic regression model with treatment group as 
the classification variable and study, baseline MSWS-12 score, baseline TUG speed, age, and 
screening EDSS score as covariates. Missing individual baseline MSWS-12 scores were 
imputed using the respondent-specific mean score of the MSWS-12 questionnaire if at least 
50% of the component questions were answered. For the MOBILE study, if less than 50% of the 
component questions were answered, then the MSWS-12 score at baseline was not imputed 
and was considered missing. For the ENHANCE study, if at least 50% of the MSWS-12 
component questions are answered, MSWS-12 score was calculated using the answered 
components. If at least 50% of the component questions were not answered, the MSWS-12 
score was considered missing. Missing individual post-baseline MSWS-12 scores were imputed 
using a multiple imputation (MI) method [Little et al.] (50 times) for each study separately, and 
the imputed data were then combined before the pooled analysis. A similar analysis compared 
the proportion of PwMS with a ≥15% mean improvement in TUG speed between treatment 
groups, and missing TUG speed individual post-baseline scores were handled as described 
above. 
A mixed model for repeated measures (MMRM) compared changes from baseline over 
24 weeks between treatment groups for the MSWS-12, TUG speed, BBS, MSIS-29 PHYS, and 
the EQ-5D-3L VAS and utility index score. Treatment, visit, and treatment by visit interaction 
were included in the models as explanatory variables. Corresponding baseline values for each 
measure, study, and screening EDSS score were included as covariates in the model. The 
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MSWS-12 model also adjusted for baseline TUG speed prior to fitting the model. For BBS and 
EQ-5D-3L endpoints, only the post-baseline assessments that were common to both studies 
were included in the model. In MOBILE, the missing values of MSWS-12, BBS, MSIS-29, EQ-
5D and TUG were not imputed. In ENHANCE, missing MSWS-12, BBS, MSIS-29 PHYS, and 
TUG individual post-baseline scores were imputed using the MI method as described above, 
whereas, for the EQ-5D endpoint, the data from both studies were first combined, and then the 
missing scores were imputed using the MMRM method. 
Similar analyses were conducted to evaluate each study outcome in people who met the 
criteria of a PR-fampridine MSWS-12 responder compared with PR-fampridine MSWS-12 
nonresponders and placebo-treated participants. A PR-fampridine MSWS-12 responder was 
defined as a participant who received treatment with PR-fampridine and had a mean 
improvement of 8 or more points in MSWS-12 score from baseline over 24 weeks. 
All summaries and statistical analyses were generated using the SAS® Version 9.4 
software package (SAS® Institute Inc., Cary, North Carolina, USA). 
 
Subgroup analyses 
Additional efficacy analyses were performed in specific subgroups of participants to determine 
whether the treatment effects observed in MOBILE and ENHANCE were heterogeneous across 
subgroups. The prespecified subgroups were stratified by age (≤45 or >45 years), gender, body 
mass index, MS disease type, median MS duration (≤10 or >10 years), EDSS score (≤6.0 or 
>6.0), median baseline MSWS-12 score (≤69.8 or >69.8), and whether the participants had 
received physiotherapy. Interaction tests were performed on each subgroup to confirm the 
observations from between-treatment group comparisons for each baseline characteristic. 
 
Results 
Participants 
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The ITT population for this integrated efficacy analysis comprised 765 participants who were 
randomized to receive PR-fampridine (n = 383) or placebo (n = 382). Baseline characteristics 
between MOBILE and ENHANCE were generally similar between the treatment groups with 
respect to demographics (age, gender, and BMI) and clinical characteristics, except that 
MOBILE enrolled more participants with secondary progressive MS and ENHANCE enrolled 
more participants with relapsing-remitting MS (Table 1).  
 
Efficacy 
Figure 2a shows that a greater proportion of PR-fampridine–treated PwMS than placebo-treated 
PwMS achieved a clinically meaningful 8-point or greater mean improvement in the MSWS-12 
over 24 weeks (44.3% vs 33.0%). PwMS receiving PR-fampridine were more likely than PwMS 
receiving placebo to obtain at least an 8-point mean improvement in the MSWS-12 over 24 
weeks (OR, 1.68; 95% CI, 1.23–2.29; p < 0.001). Adjusted least squares mean (LSM) change 
from baseline in MSWS-12 score at every visit up to week 24, and over the 24-week treatment 
period, are shown in Figure 3a and Table S1. The LSM improvements from baseline in the PR-
fampridine group relative to the placebo group were detected by week 2 and sustained over 24 
weeks. Overall, PR-fampridine was associated with a LSM improvement of 3.70 points in 
MSWS-12 score relative to placebo over 24 weeks of treatment (95% CI, -5.61 to -1.79; p < 
0.001).  
The PR-fampridine group demonstrated greater LSM improvements in mobility and 
balance based on the objective TUG and clinician-assessed BBS measures compared with the 
placebo group (Figure 3b and 3c). A greater percentage of PR-fampridine-treated participants 
had a ≥15% mean improvement in TUG speed versus placebo-treated participants (44.1% vs 
34.5%, OR, 1.54; 95% CI, 1.13–2.11; p = 0.007; Figure 2b). Over 24 weeks of treatment, the 
PR-fampridine-treated group had significantly greater LSM improvements in MSIS-29 PHYS 
score compared with the placebo group (Figure 3d). Numerical improvements from baseline 
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over 24 weeks were observed with PR-fampridine versus placebo on the EQ-5D-3L VAS and 
utility index scores; however, these results were not statistically significant (Figures 3e and 3f). 
 
PR-fampridine MSWS-12 responder analyses 
Compared with PR-fampridine MSWS-12 non-responders and placebo–treated participants, 
PR-fampridine MSWS-12 responders demonstrated greater LSM improvements across all 
efficacy outcomes over 24 weeks. LSM improvement in MSWS-12 score from baseline over 24 
weeks was -15.95 points versus placebo and -22.08 points versus PR-fampridine 
nonresponders (Figure 4a). The percentage of PR-fampridine MSWS-12 responders with a 
≥15% mean improvement in TUG speed was 53.9% compared with 36.3% among PR-
fampridine nonresponders (OR, 2.33; 95% CI, 1.50–3.61; p < 0.001) and 34.5% among 
placebo-treated PwMS (OR, 2.46; 95% CI, 1.66–3.65; p < 0.001). PR-fampridine MSWS-12 
responders demonstrated greater LSM improvements from baseline in TUG speed, BBS score, 
MSIS-29 PHYS score, and EQ-5D-3L VAS and utility index scores versus PR-fampridine 
MSWS-12 nonresponders and placebo based on LSM 95% CIs excluding zero (Figure 4, Table 
S1). Differences between responders and nonresponders in MSWS-12, TUG, BBS and MSIS-
29 PHYS outcomes were evident by Week 2 and in the EQ-5D-3L utility index by the first 
assessment at Week 4 (Figure 4a-d, f). PR-fampridine MSWS-12 nonresponders and placebo-
treated participants had similar LSM changes from baseline in TUG speed and BBS score over 
24 weeks (Table S1). However, PR-fampridine MSWS-12 nonresponders had LSM worsening 
from baseline over 24 weeks in MSWS-12 and MSIS-29 PHYS scores while the placebo group 
demonstrated some improvement. PR-fampridine MSWS-12 nonresponders had a small 
improvement from baseline although not as much as in placebo patients. Both the PR-
fampridine MSWS-12 nonresponders and placebo groups worsened from baseline in EQ-5D-3L 
utility index by week 24, with greater worsening occurring in nonresponders (Figure 4a-d). 
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Subgroup analyses 
Some participant baseline characteristics showed a statistically significant difference between 
PR-fampridine and placebo, including age >45 years, male sex, BMI between 18.5 to 24.9, 
RRMS, EDSS score ≤6.0, or baseline MSWS-12 score at or below the median (i.e., ≤69.79 
points). The P values from the interaction test for each subgroup were not significant (range, 
0.064–0.961) indicating there was no apparent heterogeneity of effect of PR-fampridine across 
the subgroups evaluated.  
 
Discussion  
This integrated analysis of MOBILE and ENHANCE provides a more precise estimate of the 
benefits of PR-fampridine on self-reported walking, self-reported physical function, objectively 
measured mobility, balance and quality of life. The pooled analysis included more than 380 
PwMS per treatment group with a range of MS subtypes. The results confirm and extend the 
findings from the individual studies [Hupperts et al., 2016, Hobart et al., 2019] and related work 
[Goodman et al., 2014, Macdonell et al., 2016, Zorner et al., 2016]. Moreover, data from 
subgroup analysis suggests that PR-fampridine has a consistent effect across a range of 
subgroups of PwMS.  
As in ENHANCE and MOBILE [Hupperts et al., 2016, Hobart et al., 2019], the pooled 
PR-fampridine group had significantly higher proportions of PwMS with clinically meaningful 
MSWS-12 and TUG speed improvements than the placebo group over 24 weeks. In addition, 
similar to the individual studies [Hupperts et al., 2016, Hobart et al., 2019], significant 
differences in favor of PR-fampridine over placebo regarding LSM improvements in MSWS-12 
score, TUG speed, and MSIS-29 PHYS over 24 weeks of treatment were detected, with 
improvements evident by Week 2 and sustained over 24 weeks. Treatment differences in EQ-
5D-3L VAS and utility index scores did not reach statistical significance.  
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LSM improvements from baseline in BBS score were significantly greater in the PR-
fampridine-treated group versus the placebo group over 24 weeks (p = 0.021). In MOBILE 
[Hupperts et al., 2016], PR-fampridine resulted in greater improvements from baseline in BBS 
score compared with placebo (during the 24-week treatment period). However, due to the 
exploratory nature of MOBILE, formal statistical testing between treatment groups was not 
conducted for this endpoint [Hupperts et al., 2016]. In ENHANCE, the improvement in BBS 
observed with PR-fampridine versus placebo did not reach statistical significance [Hobart et al., 
2019].  
It is important to consider these results within the context of the potential limitations of 
the outcomes measures to detect change in the populations of MOBILE and ENHANCE. An 
examination of BBS measurement performance using MOBILE data suggested that the BBS 
may not accurately reflect deficits in balance and has limited ability to detect change, thus 
potentially underestimating the impact of PR-fampridine on balance in MOBILE and ENHANCE 
[Hobart, 2018, Hobart et al., 2019]. Despite these limitations, the increased statistical power of 
the pooled analysis confirmed the benefits on PR-fampridine on clinician-reported static and 
dynamic balance. 
The magnitude of improvement was consistently greater with PR-fampridine, although 
some improvements were observed in the placebo group on a range of efficacy measures. A 
significantly greater percentage of PR-fampridine-treated PwMS attained a clinically meaningful 
mean improvement of ≥8 points in MSWS-12 score compared with the placebo group, indicating 
that active treatment reduced self-assessed ambulation-related disability. 
The use of a mean improvement of 8 or more points in MSWS-12 score to define a 
responder was supported by marked benefits in MSWS-12, TUG speed, BBS, and MSIS-29 
PHYS, and EQ-5D-3L VAS and utility index among PR-fampridine MSWS-12 responders 
compared with PR-fampridine MSWS-12 nonresponders and placebo-treated participants. 
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Differences between PR-fampridine MSWS-12 responders and nonresponders were evident by 
week 2 and were sustained over 24 weeks.  
The broad range of clinical benefits associated with PR-fampridine is consistent with its 
putative mechanism of action in blocking voltage-dependent potassium channels in 
demyelinated nerve fibers [Dunn et al., 2011]. A key strength of this analysis was the 
robustness of the efficacy data, which were collected from 2 near-identical, double-blind, 
randomized, placebo-controlled clinical trials. The MSWS-12, TUG, and MSIS-12 were 
assessed at the same time points in each study, and temporal BBS and EQ-5D-3L data were 
reported only when there was overlap between MOBILE and ENHANCE.  
 
Limitations 
o EQ-5D mapping 
o P values nominal (multiple comparisons)   
 
Conclusions 
Results of the integrated analysis were consistent with individual clinical trials in demonstrating 
that PR-fampridine improves walking ability, dynamic and static balance and quality-of-life over 
24 weeks in PwMS across a range of MS subtypes, including progressive MS. Use of a 
prospectively-defined MSWS-12 responder analysis is supported by the substantial benefits 
observed across all ambulatory outcome measures, which was accompanied by improvements 
in disease-specific and generic measures of health states.  
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Table 1. Baseline demographic and disease characteristics 
 MOBILE ENHANCE Pooled analysis 
Characteristic Placebo n=64 
PR-fampridine 
n=68 
Placebo 
n=318 
PR-fampridine 
n=315 
Placebo 
n=381 
PR-fampridine 
n=383 
Mean (95% CI) age, y 49.8  (47.5 to 52.1) 
49.8  
(47.7 to 51.9) 
48.8  
(47.6 to 50.0) 
49.0  
(47.9 to 50.0) 
49.0 
(47.9 to 50.0) 
49.1 
(48.1 to 50.1) 
Female, % (95% CI) 52  (39.3 to 63.8) 
56  
(44.1 to 67.7) 
57  
(51.2 to 62.1) 
59  
(53.6 to 64.5) 
56 
(50.8 to 60.7) 
58 
(53.6 to 63.4) 
Mean (95% CI) body mass 
index, kg/m2 
26.5  
(24.9 to 28.0) 
26.8  
(25.6 to 28.0) 
25.1  
(24.6 to 25.6) 
25.6  
(25.1 to 26.2) 
25.3 
(24.9 to 25.8) 
25.8 
(25.4 to 26.3) 
Mean (95% CI) time since 
first MS diagnosis, y 
12.4  
(10.3 to 14.5) 
10.9  
(9.2 to 12.5) 
11.4  
(10.5 to 12.2) 
11.5  
(10.6 to 12.3) 
11.5 
(10.7 to 12.3) 
11.4 
(10.6 to 12.1) 
Mean (95% CI) EDSS 
score 
5.85  
(5.63 to 6.07) 
5.58 
(5.35 to 5.81) 
5.48  
(5.38 to 5.58) 
5.49 
(5.39 to 5.59) 
5.54 
(5.45 to 5.63) 
5.51 
(5.41 to 5.60) 
Outcome measure,  
mean (SD) 
 
 
 
 
     
MSWS-12 score 75.90 (19.76) 71.69 (19.29) 65.39 (21.92) 63.61 (21.67) 67.15 (21.91) 65.04 (21.46 
TUG speed, m/s 0.34 (0.17) 0.38 (0.15) 0.38 (0.20) 0.38 (0.19) 0.37 (0.20) 0.38 (0.18 
BBS score 39.27 (12.34) 40.92 (11.91) 40.24 (11.84) 40.55 (11.64) 40.05 (11.91) 40.62 (11.67) 
MSIS-29 PHYs score 53.0 (19.09) 50.93 (19.40) 55.29 (21.04) 52.44 (21.12) 54.90 (20.72) 52.17 (20.81) 
EQ-5Dutility index 
score† 0.51 (0.23) 0.54 (0.20) 0.61 (0.20) 0.61 (0.21) 0.59 (0.21) 0.60 (0.21) 
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EQ-5D-5L VAS 59.10 (19.76) 61.63 (17.74) 56.98 (18.31) 60.91 (18.03) 57.33 (18.55) 61.04 (17.96) 
MS subtype, % (95% CI)       
Relapsing-remitting 31  (19.9 to 42.6) 
35  
(23.9 to 46.7) 
49  
(43.2 to 54.2) 
54 
(48.1 to 59.2) 
46  
(40.8 to 50.8) 
50  
(45.4 to 55.4) 
Secondary progressive 58  (45.7 to 69.9) 
46  
(33.8 to 57.4) 
31 
(26.0 to 36.2) 
30 
(25.1 to 35.2) 
36  
(30.8 to 40.4) 
33  
(28.2 to 37.6) 
Primary progressive 9  (2.2 to 16.5) 
18  
(8.6 to 26.7) 
14 
(10.3 to 18.0) 
13 
(9.3 to 16.7) 
13 
(9.9 to 16.8) 
14  
(10.4 to 17.3) 
Progressive relapsing 2 (0.0 to 4.6) 
1 
(0.0 to 4.3) 
6 
(3.4 to 8.6) 
3 
(1.2 to 5.1) 
5 
(3.0 to 7.5) 
3  
(1.2 to 4.5) 
EDSS = Expanded Disability Status Scale; MS = multiple sclerosis; PR = prolonged-release. 
†MOBILE used the 5-level classification system of the EQ-5D (EQ-5D-5L) [Hupperts et al., 2016]; ENHANCE used the 3-level EQ-5D 
(EQ-5D-3L) [Hobart et al., 2017]; and the pooled analysis used the “crosswalk” method, developed by the EuroQol Group, to map the 
EQ-5D-5L data to the EQ-5D-3L UK value set before calculating the utility index score [Van Hout et al., 2012]. 
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Figure legends 
Figure 1. Study design and assessment schedule in MOBILE and ENHANCE. 
 
BBS: Berg Balance Scale; EDSS: Expanded Disability Status Scale; EQ-5D-5L and -3L: 5-level 
and 3-level classification systems of the EuroQol 5-dimensions; HRQoL: health-related quality 
of life; MSIS-29 PHYS: Multiple Sclerosis Impact Scale physical subscale; MSWS-12: 12-item 
Multiple Sclerosis Walking Scale; PR: prolonged-release; TUG: Timed Up and Go.  
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Figure 2. Percentage of PwMS in the pooled MOBILE/ENHANCE ITT population with (a) mean 
MSWS-12 score improvement of ≥8 points over 24 weeks†,‡ and (b) ≥15% mean improvement 
in TUG speed†,# b. 
 
†Percentage based on binomial proportions. OR, 95% CI, and P value calculated using logistic 
regression model adjusted for study, baseline MSWS-12 score, baseline TUG speed, age and 
screening EDSS score (missing data imputed using multiple imputation). 
‡Minimally important change threshold.[Mehta et al., 2015] 
#Positive score (and increase) indicates improvement. 
CI: confidence interval; EDSS: Expanded Disability Status Scale; MSWS-12: 12-item Multiple 
Sclerosis Walking Scale; OR: odds ratio; PR: prolonged-release; TUG: Timed Up and Go 
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Figure 3. LSM change from baseline in MSWS-12 score (a), percentage change in TUG speed 
(b), BBS score† (c), MSIS-29 PHYS score (d), EQ-5D-3L VAS score† (e) and EQ-5D-3L utility 
index score† (f) over 24 weeks. Analyses were done in the pooled ITT population with a mixed 
model for repeated measures. †Analysis includes only those visits that were common between 
the MOBILE and ENHANCE studies. 
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BBS: Berg Balance Scale; CI: confidence interval; EQ-5D-3L: 3-Level EuroQol 5-dimensions; 
LSM: least squares mean; MSIS-29 PHYS: Multiple Sclerosis Impact Scale physical subscale; 
MSWS-12: 12-item Multiple Sclerosis Walking Scale; PR: prolonged-release; TUG: Timed Up 
and Go; VAS: visual analog scale.  
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Figure 4. LSM change from baseline in MSWS-12 score (a), percentage change in TUG speed 
(b), BBS score‡ (c), MSIS-29 PHYS score (d), EQ-5D-3L VAS score‡ (e) and EQ-5D-3L utility 
index score‡ (f) over 24 weeks in PR-fampridine MSWS-12 responders, PR-fampridine MSWS-
12 nonresponders, and placebo-treated people. Analyses were done in the pooled ITT 
population with a mixed model for repeated measures. †Subgroup comparisons are LSM (95% 
CI) differences over 24 weeks. ‡Analysis includes only those visits that were common between 
the MOBILE and ENHANCE studies. 
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BBS: Berg Balance Scale; CI: confidence interval; EQ-5D-3L: 3-Level EuroQol 5-dimensions; 
LSM: least squares mean; MSIS-29 PHYS: Multiple Sclerosis Impact Scale physical subscale; 
MSWS-12: 12-item Multiple Sclerosis Walking Scale; PR: prolonged-release; TUG: Timed Up 
and Go; VAS: visual analog scale. 
